Ligand Pharmaceuticals (LGND) Other Non-Current Assets (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 17 years of Other Non-Current Assets data on file, last reported at $13.0 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Assets rose 64.56% year-over-year to $13.0 million; the trailing twelve-month figure through Mar 2026 stood at $13.0 million (up 64.56% YoY), and the FY2025 full-year result was $12.6 million, down 60.35% from the prior year.
• Other Non-Current Assets climbed to $13.0 million in Q1 2026, from $12.6 million in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $31.7 million in Q4 2024 to a low of $1.7 million in Q4 2022.
• A 5-year average of $9.0 million and a median of $7.9 million in 2025 frame the typical range for Other Non-Current Assets.
• Across the five-year window, Other Non-Current Assets surged 396.4% in 2024 and slumped 67.03% in 2025, its largest moves.
• Tracing LGND's Other Non-Current Assets over 5 years: stood at $1.7 million in 2022, then jumped by 268.2% to $6.4 million in 2023, then jumped by 396.4% to $31.7 million in 2024, then tumbled by 60.35% to $12.6 million in 2025, then advanced by 3.22% to $13.0 million in 2026.
• Business Quant data shows LGND's Other Non-Current Assets at $13.0 million in Q1 2026, $12.6 million in Q4 2025, and $2.8 million in Q3 2025.